HIVEC – cystectomy saving alternative for patients with high risk superficial TCC or BCG non-responders
February 2020

At the ASCO Genitourinary Cancers Symposium 2020 in San Francisco, Prof. Thomas-Alexander Vögeli from the University Hospital RWTH Aachen, Germany presented very promising results of first two year follow up after the Hyperthermic Intra-VEsical Chemotherapy (HIVEC) with heated mitomycin in a cohort of patients with high risk superficial bladder cancer (TCC).

In this cohort of 58 patients with a high rate of BCG non-responders only 8 patients had to undergo cystectomy during a two year follow up. According to Prof. Vögeli, intravesical therapy with heated mitomycin is safe and well tolerated and may be an additional alternative treatment before cystectomy is performed in high risk patients with high risk TCC or BCG non responders.

Read more in Journal of Clinical Oncology:
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.6_suppl.512

Back to main Go to news
This site uses cookies to improve your user experience. You may find out more about in our Privacy Policy. By using this website you accept our use of cookies.
OK